Cancer vaccine composition

Abstract

A cancer vaccine composition for human leukocyte antigen (HLA)-A*0206-positive persons, comprising a protein product of the tumor suppressor gene WT1 or a partial peptide thereof.

1 - 15 : (canceled) 
     
     
         16 . A cancer vaccine composition for HLA-A*0201-positive persons, comprising the following peptide:
 a modified peptide of the WT1 187  peptide: Ser Leu Gly Glu Gln Gln Tyr Ser Val (SEQ ID NO: 2) or the WT1 126  peptide: Arg Met Phe Pro Asn Ala Pro Tyr Leu (SEQ ID NO: 3), either of which is a partial peptide of a protein which is a gene product of the tumor suppressor gene WT1, the modified peptide being immunogenic in HLA-A*0201-positive persons.   
     
     
         17 . The composition according to  claim 16 , wherein the modified peptide is
 the WT1 187 P1F peptide: Phe Leu Gly Glu Gln Gln Tyr Ser Val (SEQ ID NO: 11),   the WT1 187 P2M peptide: Ser Met Gly Glu Gln Gln Tyr Ser Val (SEQ ID NO: 16),   the WT1 187 P3M peptide: Ser Leu Met Glu Gln Gln Tyr Ser Val (SEQ ID NO: 20),   the WT1 126 P1F peptide: Phe Met Phe Pro Asn Ala Pro Tyr Leu (SEQ ID NO: 34),   the WT1 126 P2L peptide: Arg Leu Phe Pro Asn Ala Pro Tyr Leu (SEQ ID NO: 39),   the WT1 126 P3M peptide: Arg Met Met Pro Asn Ala Pro Tyr Leu (SEQ ID NO: 46) or   the WT1 126 P9V peptide: Arg Met Phe Pro Asn Ala Pro Tyr Val (SEQ ID NO: 49).   
     
     
         18 . A modified peptide of the WT1 187  peptide: Ser Leu Gly Glu Gln Gln Tyr Ser Val (SEQ ID NO: 2) or the WT1 126  peptide: Arg Met Phe Pro Asn Ala Pro Tyr Leu (SEQ ID NO: 3), either of which is a partial peptide of a protein which is a gene product of the tumor suppressor gene WT1, the modified peptide being immunogenic in HLA-A*0201-positive persons,
 for cancer treatment or prevention in HLA-A*0201-positive persons.   
     
     
         19 . A cancer vaccine composition for human leukocyte antigen (HLA)-A*0206-positive persons, comprising a protein which is a gene product of the tumor suppressor gene WT1 or a partial peptide thereof. 
     
     
         20 . The composition according to  claim 19 , wherein the protein which is a gene product of the tumor suppressor gene WT1 is the protein of the following (a) or (b):
 (a) a protein consisting of the amino acid sequence of SEQ ID NO: 1, or   (b) a protein consisting of an amino acid sequence comprising deletion, substitution or addition of one to several amino acids in the amino acid sequence (a), either of which is immunogenic in HLA-A*0206-positive persons.   
     
     
         21 . The composition according to  claim 19 , wherein the partial peptide is
 the WT1 187  peptide: Ser Leu Gly Glu Gln Gln Tyr Ser Val (SEQ ID NO: 2),   the WT1 126  peptide: Arg Met Phe Pro Asn Ala Pro Tyr Leu (SEQ ID NO: 3),   the WT1 187 P1F peptide: Phe Leu Gly Glu Gln Gln Tyr Ser Val (SEQ ID NO: 11),   the WT1 187 P2M peptide: Ser Met Gly Glu Gln Gln Tyr Ser Val (SEQ ID NO: 16),   the WT1 187 P3M peptide: Ser Leu Met Glu Gln Gln Tyr Ser Val (SEQ ID NO: 20),   the WT1 126 P1F peptide: Phe Met Phe Pro Asn Ala Pro Tyr Leu (SEQ ID NO: 34),   the WT1 126 P2L peptide: Arg Leu Phe Pro Asn Ala Pro Tyr Leu (SEQ ID NO: 39),   the WT1 126 P3M peptide: Arg Met Met Pro Asn Ala Pro Tyr Leu (SEQ ID NO: 46) or   the WT1 126 P9V peptide: Arg Met Phe Pro Asn Ala Pro Tyr Val (SEQ ID NO: 49).   
     
     
         22 . The composition according to  claim 19 , further comprising an adjuvant. 
     
     
         23 . The composition according to  claim 20 , further comprising an adjuvant. 
     
     
         24 . A cancer vaccine composition for HLA-A*0206-positive persons, comprising DNA encoding a protein which is a gene product of the tumor suppressor gene WT1 or a partial peptide thereof. 
     
     
         25 . A cancer vaccine composition for HLA-A*0206-positive persons, comprising RNA encoding a protein which is a gene product of the tumor suppressor gene WT1 or a partial peptide thereof. 
     
     
         26 . A method for inducing WT1-specific CTLs, comprising culturing, in the presence of a protein which is a gene product of the tumor suppressor gene WT1 or a partial peptide thereof, peripheral blood mononuclear cells (PBMCs) derived from an HLA-A*0206-positive person, to obtain WT1-specific CTLs induced therefrom. 
     
     
         27 . A method for inducing dendritic cells that present a protein which is a gene product of the tumor suppressor gene WT1 or a partial peptide thereof, comprising culturing, in the presence of the protein or a partial peptide thereof, immature dendritic cells derived from an HLA-A*0206-positive person, to obtain dendritic cells induced therefrom which present the protein or a partial peptide thereof. 
     
     
         28 . A method of cancer diagnosis for HLA-A*0206-positive persons, comprising
 i) a step of detecting or quantifying a protein which is a gene product of the tumor suppressor gene WT1 or a partial peptide thereof, an antibody thereagainst or WT1-specific CTLs in a sample from an HLA-A*0206-positive person, and a step of comparing the amount of the protein or a partial peptide thereof, an antibody thereagainst or the WT1-specific CTLs, with that in the case where cancer is not developed, or   ii) a step of administering an HLA-A*0206-positive subject WT1-specific CTLs induced by the method claimed in  claim 26 , and a step of determining the position or region of the CTLs or dendritic cells in the HLA-A*0206-positive subject.   
     
     
         29 . A method of cancer diagnosis for HLA-A*0206-positive persons, comprising
 i) a step of detecting or quantifying a protein which is a gene product of the tumor suppressor gene WT1 or a partial peptide thereof, an antibody thereagainst or WT1-specific CTLs in a sample from an HLA-A*0206-positive person, and a step of comparing the amount of the protein or a partial peptide thereof, an antibody thereagainst or the WT1-specific CTLs, with that in the case where cancer is not developed, or   ii) a step of administering an HLA-A*0206-positive subject dendritic cells induced by the method claimed in  claim 27 , and a step of determining the position or region of the CTLs or dendritic cells in the HLA-A*0206-positive subject.